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Abstract
Background: Low airway surface pH is associated with many airway diseases, impairs 
antimicrobial host defense and worsens airway inflammation. Inhaled Optate is 
designed to safely to raise airway surface pH and is well-tolerated in humans. Raising 
intracellular pH partially prevents activation of SARS-CoV-2 in primary normal human 
airway epithelial (NHAE) cells, decreasing viral replication by several mechanisms. 
Methods: Here, we grew primary normal human airway epithelial (NHAE) cells from 
healthy subjects, infected them with SARS-CoV-2 (isolate USA-WA1/2020), and used 
clinical Optate at concentrations used in humans in vivo to determine whether it would 
prevent viral infection and replication. Cells were pre-treated with Optate or placebo 
prior to infection (MOI of 0.1) and viral replication was determined by plaque assay and 
nucleocapsid (N) protein levels. Healthy human subjects also inhaled Optate as part of 
a Phase 2a safety trial. Results: Optate almost completely prevented viral replication at 
each time point between 24 and 120 hours, relative to placebo, both by plaque assay 
and by N protein expression (p < 0.001).  Mechanistically, Optate inhibited expression of 
major endosomal trafficking genes and raised NHAE intracellular pH.  Optate had no 
effect on NHAE cell viability at any time point.  Inhaled Optate was well tolerated in 10 
normal subjects, with no change in lung function, vital signs or oxygenation.  
Conclusions: Inhaled Optate may be well-suited for a clinical trial in patients with a 
pulmonary SARS-CoV-2 infection.  However, it is vitally important for patient safety that 
formulations designed for inhalation with regards to pH, isotonicity and osmolality be 
used. An inhalational treatment that safely prevents SARS-CoV-2 viral replication could 
be helpful for treating patients with pulmonary SARS-CoV-2 infection. 
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Introduction
Airway surface lining fluid (ALF) coats the extracellular space of the epithelial cells that 
line the airways. ALF acidification contributes to the pathophysiology of asthma and 
other respiratory diseases1-3. Specifically, ALF acidification is known to increase cough 
and bronchospasm, facilitate bacterial growth, increase mucus viscosity, decrease 
ciliary beat frequency, and cause general epithelial dysfunction2, 4-10. ALF acidification 
occurs during inflammatory and infectious airway disease exacerbations2, 6, 8-12.  
Therefore, we have been investigating the effects of raising human ALF pH using an 
inhalational treatment, Optate (Airbase Breathing Company, Indianapolis, IN). Optate is 
an inhaled isotonic, isosmotic, alkaline medication designed to safely modify airway pH 
without irritating the airway epithelium. We have previously demonstrated in several 
safety trials (Phase 1 and 2) that Optate inhalation is well tolerated in healthy humans 
and those with stable asthma and COPD9. We also demonstrated that a single 
inhalation of Optate effectively raises ALF pH, indicated by a decrease in exhaled nitric 
oxide and an increase in exhaled breath condensate pH9. 
Pandemic infection with SARS-CoV-2 (COVID-19) has cost hundreds of thousands of 
lives within the last year (www.who.int, accessed 08/09/2020).  In vitro, raising 
intracellular pH partially prevents activation of SARS-CoV-2 in primary normal human 
airway epithelial (NHAE) cells; indeed, intracellular alkalinization decreases viral 
replication by several mechanisms13-16.  Because Optate is effective at raising 
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extracellular pH in the human airway, we studied whether it would prevent SARS-CoV-2 
replication in NHAE cells. Specifically, we hypothesized that Optate would increase 
intracellular pH and decrease SARS-CoV-2 replication in NHAE cells compared to those 
treated with a placebo with the hope that it could serve as a treatment for this disease. 
Methods
Cell culture. Primary NHAE cells were grown as previously described from healthy, 
non-smoking donors17, 18. 
Study treatments.  120 mM Optate was prepared and assayed for purity, potency, 
osmolality (target ~330 mOsm), pH (target 9.8) and sterility prior to all experiments (IND 
#139144; Arena District Pharmacy, Columbus, Ohio, USA).  For the in vivo study, 10 
healthy subjects > 18 y/o with no history of lung disease was recruited under our IRB-
approved protocol (Case Western Reserve University IRB #03-18-28).  Forced 
expiratory volume in one second (FEV1), forced vital capacity (FVC), heart rate (HR), 
oxygen saturation (SpO2) and adverse events were monitored before and after one 2.5 
mL nebulization of 120 mM Optate as previously described9 and reviewed by our Data 
Safety Monitoring Board. No change was noted in any vital signs of any subject before 
and after treatment. 
For the in vitro studies, cells were exposed to the same batch of 120 mM Optate 
described above 1:1 with cell culture media to mimic the expected dilution effects of 
airway lining fluid in vivo. Phosphate-buffered saline (PBS) was used as the in vitro 
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placebo. Airway cells were acquired by brush biopsy with informed consent under 
Indiana University Institutional Review Board Protocol #1408855616. 
Intracellular pH assays. Intracellular pH was evaluated with fluorescent dyes: 1.25 μM 
2',7'-Bis-(2-Carboxyethyl)-5-(and-6)-Carboxyfluorescein, Acetoxymethyl Ester (BCECF-
AM, Invitrogen™, ThermoFisher Scientific, USA), which increases in green fluorescent 
intensity (E:E 500:531 nm) as pH increases19; and 20 μM pHrodo Red (PR, 
Invitrogen™, ThermoFisher Scientific, USA), which decreases in red fluorescent 
intensity (E:E 560:585 nm) as pH increases20. After washing (PBS) cells were treated 
with Optate (clinical solution, 1:1 dilution in medium) or PBS. As a negative control, cells 
were treated with ZnCl2, (100μM) which acidifies the intracellular space by inhibiting 
Hv121.
Viral growth and plaque assays. SARS-CoV-2 Isolate USA-WA1/2020 was provided 
by Biodefense and Emerging Infection (BEI) Resources (Manassas, VA). In our BSL3 
facility, viral stocks were prepared in Vero E6 cells (African green monkey kidney cell 
line, ATCC™, Manassas, VA) at 37oC for 2-4 days until cytopathic effect (CPE) was 
observed. Media from the cells were collected and centrifuged (1000xg; 5 min). Virus 
was quantified by plaque assay (See details in the Supplemental methods).
Vero E6 or NHAE cells were plated the day prior to the experiment. Cells were pre-
treated with Optate or PBS for 5-10 minutes prior to SARS-CoV-2 infection (MOI of 0.1). 
After one hour, cells were washed with PBS, and medium with or without Optate was 
added. For viral titers, the media was not changed prior to harvesting supernatant for 
viral titers at 24 hours post infection. Supernatant was harvested every 24 hours and 
viral replication determined by plaque assay. Data are from three experiments, each 
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done in duplicate.  NHAE infection studies used two different donors to reduce donor 
effect on results.  
Immunoblots. Using the same protocol as that for plaque assay (above) cells were 
lysed in RIPA buffer. Capillary electrophoresis was performed on the automated JESS 
system (ProteinSimple™, San Jose, CA). Briefly, 0.5ug/ul lysate was plated and run 
following manufactures recommendations. Antibodies are listed in the supplemental 
methods.  Compass software (ProteinSimple™) generated digitally-rendered bands 
based on chemiluminescence electrophoretogram.
RNA processing.  RNA was extracted from control and Optate-treated NHAE cells (48 
hr) using RNeasy™ Plus kit (Qiagen, Hilden, Germany) following the manufacturer-
recommended protocol. Total RNA was first evaluated for its quantity, and quality 
(Agilent Bioanalyzer 2100); all Samples had RNA Integrity Number of 9 or higher. Total 
RNA (100 ng) was used for cDNA library preparation and quantitation, as described in 
the supplemental methods.  More than 95% of the sequencing reads reached Q30 
(99.9% base call accuracy).
Sequenced libraries were mapped to the human genome (UCSC hg38) using STAR 
RNA-seq aligner (v.2.5) with the following parameter: “--outSAMmapqUnique 60.” Read 
distribution across the genome was assessed using bamutils (from ngsutils v.0.5.9). 
Uniquely mapped sequencing reads were assigned to hg38 refGene genes using 
featureCounts (subread v.1.5.1) with the following parameters: “-s 2 -Q 10”. Reads with 
count per million < 0.5 in more than three samples were removed. 
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Cytotoxicity assays. Cytotoxicity of Optate was measured both by lactate 
dehydrogenase (LDH) concentration (Cayman Chemical assay) and by Trypan Blue 
exclusion (Bio-Rad TC20™ automated cell counter) according to manufacturer 
specifications as previously described22. 
Data analysis.  Student’s unpaired, two-tailed t-test was used to evaluate cytotoxicity, 
pH, viral plaque, and protein levels comparing control groups and treatment groups. 
Wilcoxon rank-sum test was used for non-Gaussian distributed data as determined by 
the Shapiro-Wilk test.  Mixed effects ANOVA model was used for repeated measures, 
with a Tukey’s post-hoc correction for multiple comparisons. For RNA sequencing, gene 
symbols were converted to entrez ids using biomaRt and analyzed with the 
clusterProfiler package in R23, 24. Data were normalized using trimmed mean of M 
values. Differential expression analysis was performed using edgeR (v.3.12.1). Family 
error rate was controlled for using Bonferroni.  
Results
Optate raises intracellular pH in NHAE cells. After loading with BCECF-AM (green) 
or PR (red) dye, cells were treated with Optate or placebo and imaged for intracellular 
fluorescent intensity. Cells treated with Optate showed a significant increase in green 
fluorescent intensity (n = 4, p = 0.039) and decrease in red fluorescent intensity (n = 4, p 
= 0.001) compared to those treated with placebo, indicating an increase in intracellular 
pH (Figure 1, A and B). ZnCl2, which is known to acidify the intracellular space21, had an 
effect opposite Optate (n = 3 and 5, p = 0.036 and 0.001, Figure 1B).
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Optate decreases SARS-CoV-2 viral replication in Vero E6 and NHAE cells. SARS-
CoV-2 plaque forming units (PFUs) were measured in culture media from Optate- and 
placebo-treated Vero E6 cells (the cells used to expand viral stock) infected with SARS-
CoV-2. All cells were treated one-time, immediately after infection. Optate ablated viral 
PFUs in the Vero E6 cells (n = 3 experiments, two replicates each, p < 0.001, Figure 
2A). Under similar conditions, NHAE cells were then infected with SARS-CoV-2, treated 
with Optate or placebo, and SARS-CoV-2 PFUs and N protein levels were measured 
daily for five days. After infection was established (24 hours), both viral PFUs and N 
protein levels were ablated in the Optate-treated cells unlike the placebo-treated cells (3 
experiments using cells from two subjects, two replicates each, p < 0.001, Figure 2B-D).
Optate alters endocytosis and endosomal trafficking genes in NHAE cells. RNA 
sequencing results were compared between control and Optate-treated NHAE cells. 
Genes with significant differences between the groups are presented in a volcano plot 
(Figure 3). Genes decreased in the Optate-treated group are negative (left) and those 
that increase are positive (right). Downregulated genes for endocytosis and endosomal 
trafficking are labeled in green. Genes in blue have a Bonferroni-corrected p-value < 
0.001 and the absolute log(FC) < 1.5; magenta are Bonferroni corrected p-value < 0.001 
and the absolute log(FC) > 1.5. Genes in black are below the significance threshold of 
0.001. 
Optate is safe and well tolerated in healthy human subjects in vivo and in vitro. 
Human subjects who inhaled 120 mM Optate had no significant change in FEV1 (p = 
0.84), FVC ( p = 0.99), HR ( p = 0.42), or SpO2 (p = 0.99) after inhalation, consistent 
with previous data (Figure 4A, n = 10 normal volunteers)9. To validate that the observed 
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antiviral effects were not due to Optate killing the host cells, we evaluated cytotoxicity in 
the control and Optate-treated cells. Primary normal human airway epithelial (NHAE) 
cells exposed to 120 mM Optate, did not differ from the control group in cytotoxicity 
evaluated by Trypan Blue exclusion or lactate dehydrogenase (LDH) levels (Figure 4B). 
Discussion
Our group has previously shown that inhaled compounds can alter airway pH in vivo1, 9. 
Alterations of airway pH for therapeutic purposes have been proposed for chlorine gas 
inhalation, asthma, and cystic fibrosis1, 25, 26. These applications have all focused on 
altering extracellular pH, likely due to the fact that most commonly known toxicities of 
ALF pH disturbance are extracellular. However, most respiratory viruses require an 
intracellular acidic event within airway epithelial cells in order to enter and/or replicate13, 
16. Our findings above illustrate that Optate, which has been previously shown to 
increase ALF (extracellular) pH9, indeed raises the intracellular pH of NHAE cells and 
ablates SARS-CoV-2 viral replication post-infection. A safe, inhaled medication for 
raising intracellular pH could be of benefit for treating respiratory viral diseases even 
beyond SARS-CoV-2. 
This work has several limitations. As with any in vitro experiment, the cell culture 
models used here are not necessarily representative of the in vivo systems and disease 
processes and our observations may translate. Moreover, COVID-19 involves many 
physiologic processes downstream from SARS-CoV-2 infection and replication. It is 
possible that different therapeutic targets rather than viral replication will be necessary 
to benefit patients. However, the fact that Optate inhalation does alkalinize the 
extracellular milieu in vivo does suggest the observed effects may occur in patients with 
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SARS-CoV-2. Thus, we are preparing to conduct a randomized, placebo-controlled, 
multicenter trial to better evaluate the therapeutic value of Optate. There were also 
technical limitations regarding the experiments used. For instance, viral infection of 
NHAE cells took over 24 hours and resulted in lower titers than in Vero E6 cells. This 
was previously observed in NHAE infection models of SARS-CoV-127, 28 and therefore 
unsurprising, however, it did warrant validation in several replicates and the use of 
multiple cell lines. Further studies are warranted to optimize this model, including 
evaluation of different time courses, the ability for viral replication to occur after 
treatment cessation, and the duration of effects. Finally, although our results suggest 
our mechanism of action results from intracellular alkalinization leading to altered 
endocytic pathways and endosomal trafficking, there could be other mechanisms by 
which Optate ablates SARS-CoV-2 infection in Vero E6 and NHAE cells. 
Inhalation of pH-altering compounds should be done with caution. Exposures to pH 
above 10 and below 6.5 are known to adversely effect NHAE cell function7, 22. 
Moreover, inhalation of hypotonic and hyposmotic solutions, such as many intravenous 
medications, causes airway irritation, bronchial hyperreactivity and coughing29. Our 1:1 
PBS/cell culture media placebo group had a pH of 8 and still had significant viral 
infection, suggesting a fairly narrow therapeutic window for this purpose. Therefore, a 
specific formulation designed for inhalation with regards to isotonicity and osmolality 
that is buffered to an ideal pH within the therapeutic window needed to inhibit viral 
replication is required. 
Conclusion
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Optate raises intracellular pH and prevents SARS-CoV-2 replication in NHAE cells.  
Inhaled Optate raises ALF pH in human subjects. It is non-toxic in vitro and in vivo, 
suggesting that a clinical trial to prevent treat life-threatening SARS-CoV-2 respiratory 
infection could be contemplated.
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Quick Look
Current Knowledge. Low airway epithelial surface pH impairs antimicrobial host 
defense and worsens airway inflammation. Low airway epithelial intracellular pH 
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facilitates SARS-CoV-2 cell entry and replication. Inhaled Optate is designed to raise 
airway epithelial surface pH.
What This Paper Contributes to Our Knowledge. At the dose inhaled in human trials, 
Optate raises airway epithelial intracellular pH and almost completely prevents SARS-
CoV-2 replication in NHAE cells, ablating both viral plaque formation and nucleocapsid 
protein expression.  Optate is thus an effective anti-viral in vitro that is established to be 
safe for human inhalation in healthy subjects.
Figure Legends
Figure 1. Optate raises intracellular pH of NHAE cells. (A) Optate raised intracellular 
pH. NHAE cells were loaded with BCECF-AM, which increases in fluorescence intensity 
as pH increases across the physiological range19 (top), or pHrodo Red, which 
decreases in fluorescence intensity as pH increases20 (bottom).  Cells were imaged 
before or after treatment. (B) Fluorescent intensity increased in cells loaded with 
BCECF-AM and decreased in cells loaded with PR (n = 4 each; p = 0.039 and 0.001, 
respectively). As a control, we treated cells with ZnCl2, which acidifies the intracellular 
space by inhibiting voltage-gated proton channel Hv121.  Zinc had an effect opposite 
Optate (n = 3 and 5; p = 0.036 and 0.001, respectively). Means are reported with wide 
bars and standard error is indicated by whiskers. 
Figure 2. Optate decreases SARS-CoV-2 viral replication in Vero E6 and NHAE 
cells. (A) PFUs were measured in culture media from control and Optate-treated Vero 
E6 cells infected with SARS-CoV-2. Optate ablated viral infection in the Vero E6 cells (n 
= 3 experiments, two replicates each, p < 0.001). Means are represented with wide bars 
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and standard error is represented by whiskers. (B) Control and Optate-treated primary 
NHAE cell cultures were then infected with SARS-CoV-2 and PFUs in culture media 
were analyzed under similar conditions from 24 hr for 120 hr after infection. After 
infection was established (24 hours), viral infection was ablated in the Optate-treated 
cells (3 experiments using cells from two subjects, two replicates each, p < 0.001). Dots 
represent means and whiskers represent standard error. (C and D) N protein 
expression was then studied in cell lysates from NHBE cells described in 2B. SARS-
CoV-2 N protein expression, normalized to β-actin, was almost completely suppressed 
at time points after 24 hours (p < 0.001). Means are represented with wide bars and 
standard error is represented by whiskers. 
Figure 3. Optate alters endocytosis and endosomal trafficking genes in NHAE 
cells. RNA sequencing results were compared between control and Optate-treated 
NHAE cells. Genes with significant differences between the groups are presented in a 
volcano plot. Genes decreased in the Optate-treated group are negative (left) and those 
that increase are positive (right). Downregulated genes for endocytosis and endosomal 
trafficking are labeled in green. Genes in blue have a Bonferroni-corrected p-value < 
0.001 and the absolute log(FC) < 1.5; magenta are Bonferroni corrected p-value < 0.001 
and the absolute log(FC) > 1.5. Genes in black are below the significance threshold of 
0.001. A list of downregulated genes is provided in the supplemental results. 
Figure 4. Optate safely is well tolerated in the human airway in vitro and in vivo. 
(A) Human subjects had no significant change in FEV1 (p = 0.84), FVC ( p = 0.99), HR ( 
p = 0.42), or SpO2 (p = 0.99) after Optate inhalation (n = 10 normal volunteers). Dots 
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represent means. (B) NHAE cells exposed to Optate for five days did not differ from the 
control group in cytotoxicity evaluated by LDH levels (Top) or % viability determined by 
Trypan Blue exclusion (Bottom). Means are represented with wide bars and standard 
error is represented by whiskers. 
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